Malignancy of squamous histology. In cases of mixed histology, squamous must be the predominant histology.
Has non-squamous histology NSCLC.
Patients must have histologic or cytological diagnosis of advanced/metastatic NSCLC with no curative treatment options; for those with mixed histology, there must be a predominant histology
Histology other than squamous cell carcinoma
Patients with lung cancer with squamous histology
Patients with squamous cell histology or non-squamous cell histology previously treated by pemetrexed and with a contraindication for docetaxel with grade ?  neuropathy or hypersensitivity reaction to medications formulated with polysorbate  (Tween ) as they could be randomly assigned to Arm B.
Squamous cell histology or mixed, predominantly squamous adenosquamous carcinoma
Histologically-confirmed diagnosis of high risk non-muscle-invasive (T, high grade Ta and / or carcinoma in situ [CIS]) transitional cell carcinoma of the bladder (mixed histology tumors allowed if transitional cell histology is predominant histology).
Patients must have histologic or cytologic diagnosis of advanced/metastatic NSCLC. For those with mixed histology, there must be a predominant histology.
Has predominantly squamous cell histology NSCLC.
Non-squamous histology including lymphoma, neuroendocrine carcinoma, adenocarcinoma, or other histology
Histology other than squamous cell carcinoma
Patients with a diagnosis of intrathoracic lung carcinoma of squamous cell histology are not eligible for participation
Patients must not have hemoptysis, squamous histology, brain metastasis
Histology other than squamous cell carcinoma
Patients with mixed histology SCLC and NSCLC are permitted
Patients with non-squamous cell histology
Squamous or mixed histology (eg, adenosquamous) NSCLC
Positive for KRAS mutation or Squamous cell histology
Mixed tumor histology
Tumors with squamous cell histology
Participants who have squamous histology.
